Health Insurance (Section 3C General Medical Services – Transcatheter Aortic Valve Implantation) Amendment Determination 2023

I, Louise Riley, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 14 December 2023 

Louise Riley

Assistant Secretary

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments

Health Insurance (Section 3C General Medical Services – Transcatheter Aortic Valve Implantation) Determination 2018

1  Name

  This instrument is the Health Insurance (Section 3C General Medical Services – Transcatheter Aortic Valve Implantation) Amendment Determination 2023.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 3C(1) of the Health Insurance Act 1973.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

Health Insurance (Section 3C General Medical Services – Transcatheter Aortic Valve Implantation) Determination 2018

1  Schedule 1 (cell at item 38495, column 2)

Repeal the cell, substitute:

TAVI, for the treatment of symptomatic severe aortic stenosis, performed via transfemoral delivery, unless transfemoral delivery is contraindicated or not feasible, if:

(a) the TAVI Patient is at high risk for surgery; and

(b) the service:

(i) is performed by a TAVI Practitioner in a TAVI Hospital; and

(ii) includes all intraoperative diagnostic imaging that the TAVI Practitioner performs upon the TAVI Patient; and

(iii) includes valvuloplasty, if required;

not being a service which has been rendered within 5 years of a service to which this item or item 38514 or 38522 applies (H) (Anaes.) (Assist.)

2  Schedule 1, (cell at item 38514, column 2)

Repeal the cell, substitute:

TAVI, for the treatment of symptomatic severe aortic stenosis, performed via transfemoral delivery, unless transfemoral delivery is contraindicated or not feasible, if:

(a) the TAVI Patient is at intermediate risk for surgery; and

(b) the service:

(i) is performed by a TAVI Practitioner in a TAVI Hospital; and

(ii) includes all intraoperative diagnostic imaging that the TAVI Practitioner performs upon the TAVI Patient; and

(iii) includes valvuloplasty, if required;

not being a service which has been rendered within 5 years of a service to which this item or item 38495 or 38522 applies (H) (Anaes.) (Assist.)

3  Schedule 1, (cell at item 38522, column 2)

Repeal the cell, substitute:

TAVI, for the treatment of symptomatic severe native calcific aortic stenosis, performed via transfemoral delivery, unless transfemoral delivery is contraindicated or not feasible, if:

(a) the TAVI Patient is at low risk for surgery; and

(b) the service:

(i) is performed by a TAVI Practitioner in a TAVI Hospital; and

(ii) includes all intraoperative diagnostic imaging that the TAVI Practitioner performs upon the TAVI Patient; and

(iii) includes valvuloplasty, if required;

not being a service which has been rendered within 5 years of a service to which this item or item 38495 or 38514 applies (H) (Anaes.) (Assist.)